Alcon AG vs Innodata Inc — how do they compare? Alcon AG trades at $73.71 (market cap $36.44B), while Innodata Inc trades at $61.65 (market cap $2.05B). The key difference: Alcon AG is far larger — about 17.8× Innodata Inc's market cap, and Alcon AG pays a 0.48% dividend while Innodata Inc pays none. Which is the better fit depends on your goals.
| ALC | INOD | |
|---|---|---|
Market Cap | $36.44B | $2.05B |
Sector | Health | Technology |
52-Week High | $90.12 | $121.50 |
52-Week Low | $62.02 | $34.45 |
Enterprise Value | $40.28B | $1.80B |
Dividend Yield | 0.48% | — |
Signals from Pluang's Aura AI — not financial advice
ALC trades at $73.525, down 0.14% on the day, with a bullish technical signal from moving averages and positive analyst sentiment. Recent Q2 2026 earnings beat estimates, with revenue of $10.4 billion in 2025 and a net income margin of 5.92%. The company raised its 2026 profitability outlook, citing tariff relief and strong product launches.
The stock offers a 17.9% upside to the consensus price target of $86.67, supported by bullish analyst ratings and improving cash flow trends. Key risks include elevated P/E valuation at 57.52 and potential macroeconomic pressures on medical device demand. Earnings growth and execution on new products remain critical for sustained momentum.
INOD trades at $62.26, up 0.06% on the day, with a bullish technical signal supported by oscillators and strong momentum indicators. The company reported robust Q2 2026 results, beating EPS estimates with $0.41 versus $0.21 expected, driven by 58% revenue growth and margin expansion. Analyst consensus is bullish with a $130 price target, reflecting optimism around AI-driven growth and profitability improvements.
Outlook remains positive due to accelerating AI demand and operational leverage, though the stock's premium valuation (P/E 48.62) poses a risk if growth moderates. Key opportunities include continued AI adoption and customer diversification, while risks involve execution challenges and competitive pressures in the AI services sector.
Trailing returns across standard periods
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →Innodata is a global data engineering company that provides solutions for training AI models. It helps enterprises solve complex data challenges through high-quality data annotation and digital transformation.
Read more on INOD →